Dr. Goodman is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
601 Elmwood Ave
URMC Box 605; Room 6-8521
Rochester, NY 14642Phone+1 585-275-7854Fax+1 585-275-9953
Education & Training
National Institutes of Health Clinical CenterPost-Doctoral Fellowship, Neuroimmunology & Multiple Sclerosis, 1983 - 1988
Icahn School of Medicine at Mount Sinai/Mount Sinai HospitalResidency, Neurology, 1979 - 1983
Rutgers New Jersey Medical SchoolClass of 1979
Certifications & Licensure
NY State Medical License 1981 - 2025
MD State Medical License 1985 - 1988- American Board of Psychiatry and Neurology Neurology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012
Clinical Trials
- Study of Subcutaneous Daclizumab in Patients With Active, Relapsing Forms of Multiple Sclerosis Start of enrollment: 2005 Apr 01
- Placebo vs. Linoleic Acid Controlled Assessment of Treatment Efficacy in MS Start of enrollment: 2008 Mar 01
- Lubiprostone in Patients With Multiple Sclerosis Associated Constipation Start of enrollment: 2010 Nov 01
- Join now to see all
Publications & Presentations
PubMed
- 2 citationsDisease-modifying treatment, long-term outcomes and transition to progressive multiple sclerosis: data based on the New York State MS Consortium.Dejan Jakimovski, Katelyn S Kavak, Patricia K Coyle, Andrew D Goodman, Malcolm Gottesman
Journal of Neurology. 2024-02-01 - 16 citationsHigh-dose vitamin Dsupplementation in relapsing-remitting multiple sclerosis: a randomised clinical trial.Sandra D Cassard, Kathryn C Fitzgerald, Peiqing Qian, Susan A Emrich, Christina J Azevedo
Eclinicalmedicine. 2023-05-01 - 2 citationsRecurrent Optic Neuritis and Perineuritis Followed by an Unexpected Discovery: From the National Multiple Sclerosis Society Case Conference Proceedings.Daniela A Pimentel Maldonado, Robert Lisak, Steven Galetta, Laura Balcer, Thomas Varkey
Neurology(R) Neuroimmunology & Neuroinflammation. 2023-01-01
Press Mentions
NeuroGenesis Receives FDA Clearance for Phase IIb StudyApril 24th, 2023
#AAN2019 — Ibudilast Slows Brain Atrophy in PPMS but Not SPMS Patients, Phase 2b Trial ShowsApril 4th, 2019
MediciNova Announces Upcoming Presentations Regarding the SPRINT-MS Phase 2b Trial of MN-166 (Ibudilast) in Progressive Multiple Sclerosis at the 71st American Academy of Neurology Annual Meeting in Philadelphia, PennsylvaniaMarch 24th, 2019- Join now to see all
Grant Support
- Public Prevention Health Fund: Community Transformation GrantsNational Center For Chronic Disease Prev And Health Promo2011
- Antegren/ Intramuscular Interferon Beta 1A In MSNational Center For Research Resources2000–2002
- Study Of IV Antegren In Patients With MS During Acute ExaserbationNational Center For Research Resources1998–2002
- Study To Assess Pharmacokinetics Of ESC Dose Of Fampridinein In MS PatientsNational Center For Research Resources1998–2001
- Longterm OPEN Label Study To Evaluate Safety Of Copaxone In Multiple SclerosisNational Center For Research Resources1996–1997
- Quantitative Assessment Of Fampridine For Motor Deficits In MSNational Center For Research Resources1996
- Phase II Titration Study Of Fampridine Administered BID In Multiple SclerosisNational Center For Research Resources1996
- Lymphocyte B-Adrenergic Receptors In Multiple SclerosisNational Center For Research Resources1992–1993
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
